Cerus SG&A Expenses 2010-2025 | CERS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cerus sg&a expenses from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Cerus sg&a expenses from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$216.5B
Boston Scientific (BSX)	$153.5B
Stryker (SYK)	$147.8B
EssilorLuxottica (ESLOY)	$131.6B
Medtronic (MDT)	$115B
Lonza Group Ag (LZAGY)	$49.2B
Haleon (HLN)	$42.8B
ResMed (RMD)	$38.3B
GE HealthCare Technologies (GEHC)	$34B
Agilent Technologies (A)	$31.8B
Terumo (TRUMY)	$24.2B
Koninklijke Philips (PHG)	$23.6B
Insulet (PODD)	$19.8B
Zimmer Biomet Holdings (ZBH)	$18.3B
Baxter (BAX)	$14B
Smith & Nephew SNATS (SNN)	$13.3B
Sunny Optical Technology (SNPTF)	$10.4B
Demant (WILYY)	$8.6B
Bio-Rad Laboratories (BIO)	$6.6B
Lantheus Holdings (LNTH)	$5B
Prestige Consumer Healthcare (PBH)	$3.7B
Perrigo (PRGO)	$3.7B
Haemonetics (HAE)	$3.5B
Shandong Weigao Medical Polymer (SHWGF)	$3.5B
Envista Holdings (NVST)	$3.3B
ICU Medical (ICUI)	$3B
LeMaitre Vascular (LMAT)	$1.8B
QuidelOrtho (QDEL)	$1.7B
AtriCure (ATRC)	$1.4B
Acuren (TIC)	$1.4B